Apo-Amitriptyline: Affected lots may exceed the interim acceptable intake limit for NNORT
Brand(s)
Last updated
Summary
Product
Apo-Amitriptyline
Issue
Health products - Product safety
What to do
Consult your health care professional if you have any health concerns.
Distribution
Alberta
British Columbia
Manitoba
Newfoundland and Labrador
Nova Scotia
Ontario
Quebec
Saskatchewan
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| Apo | Apo-Amitriptyline | DIN 02403137 | Tablet | Amitriptyline Hydrochloride 10 mg | RN6384, RR0265, RR0266, RV1644, RV1645, RW8597, RW8598, TA6008, TA6009, TF8585, TF8586, TF8587, TF8588, TF8589, TW2842, TW2843 |
| Apo | Apo-Amitriptyline | DIN 02403145 | Tablet | Amitriptyline Hydrochloride 25 mg | RM0519, RM8130, RR0780, RR0781, RV1656, RV1657, RW8691, TA6061, TA6062, TF8602, TF8603 |
Issue
Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-nortriptyline (NNORT)
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Previous recalls or alerts
Background
Depth of recall: Wholesalers, Retailers, Healthcare Establishments
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Apotex Inc
150 Signet Drive, Toronto, ON Canada M9L 1T9
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
Alberta
British Columbia
Manitoba
Newfoundland and Labrador
Nova Scotia
Ontario
Quebec
Saskatchewan
Recall class
Type I
Identification number
RA-76352
Get notified
Receive notifications for new and updated recalls and alerts by category.